A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.Neurology. 2017 Jan 10; 88(2):152-159.Neur
To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD.
We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach.
An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study.
These data do not justify use of CoQ as a treatment to slow functional decline in HD.
CLASSIFICATION OF EVIDENCE
This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.
- A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
- The CREST-E study of creatine for Huntington disease: A randomized controlled trial.
- Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
- Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.
- Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.
- Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
- Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.
- The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
- Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.